| MAP3K8 |
Homo sapiens |
|
MAP3K8 is differentially expressed in 108 experiments [105 up/94 dn]: 12 organism parts: kidney [0 up/2 dn], peripheral blood [1 up/1 dn], ...; 23 disease states: normal [4 up/6 dn], acute promyelocytic leukemia [1 up/1 dn], ...; 26 cell types, 28 cell lines, 26 compound treatments and 18 other conditions. |
| COT, ESTF, MAP3K8, RP11-449I17.8-004, RP11-449I17.8-006, RP11-449I17.8-005, RP11-449I17.8-001 |
|
M3K8_RAT (Rattus norvegicus)
BCK1 (Saccharomyces cerevisiae)
Map3k8 (Mus musculus)
(Compare orthologs)
|
|
|
| Mitogen-activated protein kinase kinase kinase 8, Protein kinase, catalytic domain, Protein kinase-like domain, Serine/threonine-protein kinase-like domain, Serine/threonine-protein kinase, active site |
|
|
| Lung cancer, somatic |
|
|
| ATP binding, MAP kinase kinase kinase activity, cell cycle, kinase activity, protein amino acid phosphorylation |
|
|
|
P41279
Q59FC1
Q5T853
Q5T856
Q6FG25
Q5T857
Q5T854
|
|
|
|
ENSG00000107968
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
None
|
Compound treatment |
|
|
Stromal cell
|
Cell type |
|
|
MCF-7
|
Cell line |
|
|
Kidney
|
Organism part |
|
|
BT-474
|
Cell line |
|
|
Estrogen receptor 1 negative; ...
|
Test result |
|
|
Placebo
|
Compound treatment |
|
|
MDA-MB-231
|
Cell line |
|
|
PC3
|
Cell line |
|
|
Fibroblast
|
Cell type |
|
|
Peripheral blood
|
Organism part |
|
|
MK886
|
Compound treatment |
|
|
HL-60
|
Cell line |
|
|
Cystic change
|
Histology |
|
|
Control
|
Compound treatment |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
FLAP
|
Compound treatment |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
Circulating neutrophil
|
Cell type |
|
|
Fetal bovine serum in media
|
Growth condition |
|
|
In vitro neutrophil
|
Cell type |
|
|
Postprandial lipid micelles in...
|
Growth condition |
|
|
ITS medium with albumin-bound ...
|
Growth condition |
|
|
Inter-prandial lipid micelles ...
|
Growth condition |
|
|
ITS medium
|
Growth condition |
|
|
Normal1
|
Replicate |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
Normal5
|
Replicate |
|
|
HPL1
|
Cell line |
|
|
Epithelial cell
|
Cell type |
|
|
HeLa
|
Cell line |
|
|
T47D
|
Cell line |
|
|
Mannitol
|
Compound treatment |
|
|
A549
|
Cell line |
|
|
Lymphatic endothelial cell
|
Cell type |
|
|
Acute lymphocytic leukemia
|
Disease state |
|
|
BJAB
|
Cell line |
|
|
U937
|
Cell line |
|
|
Glutamine
|
Compound treatment |
|
|
Testicular seminoma
|
Disease state |
|
|
Endothelial cell
|
Cell type |
|
|
Kaposi's sarcoma
|
Disease state |
|
|
Beas2B
|
Cell line |
|
|
Lung
|
Organism part |
|
|
U87
|
Cell line |
|
|
U373
|
Cell line |
|
|
5-aza-2'-deoxycytidine
|
Compound treatment |
|
|
Granulocyte macrophage-colony ...
|
Compound treatment |
|
|
Johnsen score count 2: Sertoli...
|
Histology |
|
|
Trichostatin A
|
Compound treatment |
|
|
Platelet-derived growth factor
|
Compound treatment |
|
|
Bladder
|
Organism part |
|
|
Bladder mucosa
|
Organism part |
|
|
MCF10A
|
Cell line |
|
|
Plasma cell
|
Cell type |
|
|
B lymphocyte
|
Cell type |
|
|
Respiratory syncytial virus
|
Infection |
|
|
Metastatic
|
Disease staging |
|
|
Native skin
|
Cell type |
|
|
Lipopolysaccharide
|
Compound treatment |
|
|
Hematopoietic stem cell
|
Cell type |
|
|
Adipose tissue-derived stem ce...
|
Cell type |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
Vasectomized
|
Clinical history |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Synovial fluid
|
Organism part |
|
|
Invasive breast cancer
|
Disease state |
|
|
T2N0M0
|
Disease staging |
|
|
Superficial transitional cell ...
|
Disease state |
|
|
SsMCF7
|
Cell line |
|
|
R-(-)-apomorphine HCl
|
Compound treatment |
|
|
Skin substitute
|
Cell type |
|
|
Estrogen receptor 1 positive; ...
|
Test result |
|
|
Lipopolysaccharide and R848
|
Compound treatment |
|
|
Actinomycin D
|
Compound treatment |
|
|
T3bN1M0
|
Disease staging |
|
|
SKMEL5
|
Cell line |
|
|
Total_RNA
|
Material type |
|
|
Polysome-associated RNA
|
Material type |
|
|
Spleen
|
Organism part |
|
|
Trigeminal ganglion
|
Organism part |
|
|
Carcinoma in situ lesion
|
Disease state |
|
|
AZ521
|
Cell line |
|
|
T47-D
|
Cell line |
|
|
Phenol
|
Compound treatment |
|
|
MDA468
|
Cell line |
|
|
Jurkat
|
Cell line |
|
|
PT3
|
Disease staging |
|
|
Huntington's disease
|
Disease state |
|
|
Sapphyrin PCI-2050
|
Compound treatment |
|
|
KSHV latent infection
|
Disease state |
|
|
Malignant melanoma
|
Disease state |
|
|
No decrease in symptoms
|
Clinical info |
|
|
Keratinocyte
|
Cell type |
|
|
Immediately after exercise
|
Clinical info |
|
|
Ultraviolet light
|
Light |
|
|
Sapphyrin PCI-2051
|
Compound treatment |
|
|
BT474
|
Cell line |
|
|
CD8+ naive CD8 T cell
|
Cell type |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
Monocyte at intermediate diffe...
|
Cell type |
|
|
Pancreatic cancer
|
Disease state |
|
|
Crohn's disease
|
Disease state |
|
|
Chronic lymphocytic leukemia
|
Disease state |
|
|
White blood cell
|
Cell type |
|
|
Platelet
|
Cell type |
|
|
Staphylococcus aureus
|
Infection |
|
|
Normal
|
Disease staging |
|
|
Uninfected
|
Infection |
|
|
Pan troglodytes
|
Organism |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
Multiple myeloma
|
Disease state |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
PT2
|
Disease staging |
|
|
Monocyte
|
Cell type |
|
|
Lin- CD34-
|
Phenotype |
|
|
IgV status unknown
|
Genotype |
|
|
M-CSF
|
Compound treatment |
|
|
Ethanol
|
Compound treatment |
|
|
Ponasterone A
|
Compound treatment |
|
|
Benign
|
Disease staging |
|
|
Unknown_sex
|
Sex |
|
|
PCep4 control vector transfect...
|
Gene modification |
|
|
ETat plasmid transfection
|
Gene modification |
|
|
Macaca mulatta
|
Organism |
|
|
Benign prostatic hyperplasia
|
Disease state |
|
|
Prostate carcinoma
|
Disease state |
|
|
Primary cells
|
Cell line |
|
|
Obesity
|
Disease state |
|
|
Pancreatic ductal adenocarcino...
|
Disease state |
|
|
Monoclonal gammopathy of undet...
|
Disease state |
|
|
PT1
|
Disease staging |
|
|
Teratozoospermia
|
Disease state |
|
|
Normospermic
|
Disease state |
|
|
Skeletal muscle
|
Organism part |
|
|
TIVE
|
Cell line |
|
|
17beta-estradiol
|
Compound treatment |
|
|
Control
|
RNAi |
|
|
SIM2s
|
RNAi |
|
|
Grade IV
|
Tumor grading |
|
|
CD4+ T cell
|
Cell type |
|
|
CD8+ T cell
|
Cell type |
|
|
Atrioventricular node
|
Organism part |
|
|
T3aNxMx
|
Disease staging |
|
|
Baseline propofol
|
Compound treatment |
|
|
Heregulin
|
Compound treatment |
|
|
KSHV-negative EBV-positive
|
Clinical info |
|
|
IBL4
|
Cell line |
|
|
Geriatric
|
Developmental stage |
|
|
Pediatric
|
Developmental stage |
|
|
Cerebellum
|
Organism part |
|
|
Lung adenocarcinoma
|
Disease state |
|
|
BDCA1+ dendritic cell
|
Cell type |
|
|
T4aNxMx
|
Disease staging |
|
|
TMK1
|
Cell line |
|
|
Sevoflurane
|
Compound treatment |
|
|
Seminiferous tubule
|
Organism part |
|
|
IgV unmutated
|
Genotype |
|
|
Infrared light
|
Light |
|
|
Kaposi's sarcoma-associated he...
|
Infection |
|
|
Primary fibroblast
|
Cell type |
|
|
CD14+ monocyte
|
Cell type |
|
|
PDGF-A dominant-negative
|
Genotype |
|
|
|
|
|
Processing time: 0.123 secs.